HanchorBio Partners With InxMed to Broaden Use of Oncology Asset HCB101
Taiwan-based HanchorBio is collaborating with InxMed on combination studies to expand the therapeutic potential of its lead oncology asset, HCB101. The partnership aims to address cancer drug resistance.
Taiwan-listed biotech HanchorBio is initiating a partnership with InxMed to explore broader applications for its lead oncology asset, HCB101. The collaboration will focus on combination research to investigate how HCB101 performs alongside InxMed's late-stage drug candidates designed to combat cancer drug resistance.
The strategic alliance aims to enhance the value of HCB101 by tackling a significant challenge in oncology: acquired resistance to cancer therapies. By combining HanchorBio's asset with InxMed's expertise in resistance mechanisms, the companies seek to improve treatment outcomes for patients who have exhausted current therapeutic options.
InxMed specializes in developing therapies that can overcome the resistance that cancer cells develop against existing treatments. This research collaboration is expected to potentially expand the market reach and therapeutic utility of HCB101. Financial terms and specific timelines for the research have not yet been disclosed. HanchorBio, traded on the Taiwan Stock Exchange under the symbol TWSE: 7827, views this partnership as a way to maximize the potential of its existing drug pipeline.